560 related articles for article (PubMed ID: 22529186)
21. Hypoxia induces CD133 expression in human lung cancer cells by up-regulation of OCT3/4 and SOX2.
Iida H; Suzuki M; Goitsuka R; Ueno H
Int J Oncol; 2012 Jan; 40(1):71-9. PubMed ID: 21947321
[TBL] [Abstract][Full Text] [Related]
22. Increased expression of CD133 is a strong predictor of poor outcome in stage I colorectal cancer patients.
Reggiani Bonetti L; Migaldi M; Caredda E; Boninsegna A; Ponz De Leon M; Di Gregorio C; Barresi V; Scannone D; Danese S; Cittadini A; Sgambato A
Scand J Gastroenterol; 2012 Oct; 47(10):1211-7. PubMed ID: 22856425
[TBL] [Abstract][Full Text] [Related]
23. The combination of stem cell markers CD133 and ABCG2 predicts relapse in stage I non-small cell lung carcinomas.
Li F; Zeng H; Ying K
Med Oncol; 2011 Dec; 28(4):1458-62. PubMed ID: 20717756
[TBL] [Abstract][Full Text] [Related]
24. Expressions of putative cancer stem cell markers ABCB1, ABCG2, and CD133 are correlated with the degree of differentiation of gastric cancer.
Jiang Y; He Y; Li H; Li HN; Zhang L; Hu W; Sun YM; Chen FL; Jin XM
Gastric Cancer; 2012 Oct; 15(4):440-50. PubMed ID: 22395309
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of CTCs and CSCs of tumor drainage vein blood in Dukes' stage B and C colorectal cancer patients.
Shimada R; Iinuma H; Akahane T; Horiuchi A; Watanabe T
Oncol Rep; 2012 Apr; 27(4):947-53. PubMed ID: 22267181
[TBL] [Abstract][Full Text] [Related]
26. Putative stemness markers octamer-binding transcription factor 4, sex-determining region Y-box 2, and NANOG in non-small cell lung carcinoma: A clinicopathological association.
Upadhyay VA; Shah KA; Makwana DP; Raval AP; Shah FD; Rawal RM
J Cancer Res Ther; 2020; 16(4):804-810. PubMed ID: 32930122
[TBL] [Abstract][Full Text] [Related]
27. Expression of CD133 and other putative stem cell markers in uveal melanoma.
Thill M; Berna MJ; Grierson R; Reinhart I; Voelkel T; Piechaczek C; Galambos P; Jager MJ; Richard G; Lange C; Gehling UM
Melanoma Res; 2011 Oct; 21(5):405-16. PubMed ID: 21900792
[TBL] [Abstract][Full Text] [Related]
28. Colon cancer stem cell markers CD44 and CD133 in patients with colorectal cancer and synchronous hepatic metastases.
Jing F; Kim HJ; Kim CH; Kim YJ; Lee JH; Kim HR
Int J Oncol; 2015 Apr; 46(4):1582-8. PubMed ID: 25625240
[TBL] [Abstract][Full Text] [Related]
29. Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma.
Song W; Li H; Tao K; Li R; Song Z; Zhao Q; Zhang F; Dou K
Int J Clin Pract; 2008 Aug; 62(8):1212-8. PubMed ID: 18479363
[TBL] [Abstract][Full Text] [Related]
30. Expressions and clinical significances of CD133 protein and CD133 mRNA in primary lesion of gastric adenocacinoma.
Yu JW; Zhang P; Wu JG; Wu SH; Li XQ; Wang ST; Lu RQ; Ni XC; Jiang BJ
J Exp Clin Cancer Res; 2010 Nov; 29(1):141. PubMed ID: 21054902
[TBL] [Abstract][Full Text] [Related]
31. Expression of nestin, CD133 and ABCG2 in relation to the clinical outcome in pediatric sarcomas.
Zambo I; Hermanova M; Zapletalova D; Skoda J; Mudry P; Kyr M; Zitterbart K; Sterba J; Veselska R
Cancer Biomark; 2016 Jun; 17(1):107-16. PubMed ID: 27314299
[TBL] [Abstract][Full Text] [Related]
32. The cancer stem cell antigens CD133, BCRP1/ABCG2 and CD117/c-KIT are not associated with prognosis in resected early-stage non-small cell lung cancer.
Herpel E; Jensen K; Muley T; Warth A; Schnabel PA; Meister M; Herth FJ; Dienemann H; Thomas M; Gottschling S
Anticancer Res; 2011 Dec; 31(12):4491-500. PubMed ID: 22199321
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value of Musashi-1 in endometrioid adenocarcinoma.
Ma L; Xu YL; Ding WJ; Shao HF; Teng YC
Int J Clin Exp Pathol; 2015; 8(5):4564-72. PubMed ID: 26191146
[TBL] [Abstract][Full Text] [Related]
34. Cancer stem cell marker CD133+ tumour cells and clinical outcome in rectal cancer.
Wang Q; Chen ZG; Du CZ; Wang HW; Yan L; Gu J
Histopathology; 2009 Sep; 55(3):284-93. PubMed ID: 19723143
[TBL] [Abstract][Full Text] [Related]
35. Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells.
Kryczek I; Liu S; Roh M; Vatan L; Szeliga W; Wei S; Banerjee M; Mao Y; Kotarski J; Wicha MS; Liu R; Zou W
Int J Cancer; 2012 Jan; 130(1):29-39. PubMed ID: 21480217
[TBL] [Abstract][Full Text] [Related]
36. The prognostic value of clinical factors and cancer stem cell-related markers in gliomas.
Dahlrot RH
Dan Med J; 2014 Oct; 61(10):B4944. PubMed ID: 25283629
[TBL] [Abstract][Full Text] [Related]
37. Expression of cancer stem cell markers in pancreatic intraepithelial neoplasias and pancreatic ductal adenocarcinomas.
Kure S; Matsuda Y; Hagio M; Ueda J; Naito Z; Ishiwata T
Int J Oncol; 2012 Oct; 41(4):1314-24. PubMed ID: 22824809
[TBL] [Abstract][Full Text] [Related]
38. Elevated circulating endothelial progenitor marker CD133 messenger RNA levels predict colon cancer recurrence.
Lin EH; Hassan M; Li Y; Zhao H; Nooka A; Sorenson E; Xie K; Champlin R; Wu X; Li D
Cancer; 2007 Aug; 110(3):534-42. PubMed ID: 17594720
[TBL] [Abstract][Full Text] [Related]
39. Prognostic impact of CD133 mRNA expression in 48 glioblastoma patients treated with concomitant radiochemotherapy: a prospective patient cohort at a single institution.
Metellus P; Nanni-Metellus I; Delfino C; Colin C; Tchogandjian A; Coulibaly B; Fina F; Loundou A; Barrie M; Chinot O; Ouafik L; Figarella-Branger D
Ann Surg Oncol; 2011 Oct; 18(10):2937-45. PubMed ID: 21479688
[TBL] [Abstract][Full Text] [Related]
40. Inflammation-related DNA damage and expression of CD133 and Oct3/4 in cholangiocarcinoma patients with poor prognosis.
Thanan R; Pairojkul C; Pinlaor S; Khuntikeo N; Wongkham C; Sripa B; Ma N; Vaeteewoottacharn K; Furukawa A; Kobayashi H; Hiraku Y; Oikawa S; Kawanishi S; Yongvanit P; Murata M
Free Radic Biol Med; 2013 Dec; 65():1464-1472. PubMed ID: 23917144
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
